Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238829 | 0.85 | MGLL (0.52) | MGLLPPARGENPP2POLBNPC1 | |
| SCHEMBL2238244 | 0.79 | PPARG (0.47) | MGLLPPARGENPP2POLBNPC1 | |
| SCHEMBL719092 | 0.78 | CYP24A1 (0.35) | ATM | |
| SCHEMBL2238136 | 0.74 | BACE1 (0.49) | MGLLPPARGENPP2BACE1 | |
| SCHEMBL15260635 | 0.74 | AOC3 (0.38) | — | |
| SCHEMBL22264292 | 0.74 | AOC3 (0.38) | RAB9A | |
| SCHEMBL22264315 | 0.74 | APLNR (0.34) | — | |
| SCHEMBL22264312 | 0.74 | APLNR (0.34) | — | |
| SCHEMBL15260634 | 0.74 | AOC3 (0.38) | — | |
| SCHEMBL15261181 | 0.74 | AOC3 (0.38) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349990-B1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LTD (GB) | 2018-05-02 | — | — | EP | disclosed |
| US-8207167-B2 | Aryl-phenyl-sulfonamide-phenylene compounds and their use | PIMCO 2664 LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | PIMCO 2664 LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2349990-A1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | Pimco 2664 Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010032010-A1 | ARYL-PHENYL-SULFONAMIDE-PHENYLENE COMPOUNDS AND THEIR USE | PIMCO 2664 LIMITED (GB) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190302-A1 | Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use | SOST, PSAP, ARSA | MGLL 4366/4885PPARG 208/4885ENPP2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.